Spero Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
675 Massachusetts Ave Ste 14, Cambridge,...Phone Number
(857) 242-1600Website
www.sperotherapeutics.comRevenue
$61.2 MillionStock Symbol
SPROIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Spero Therapeutics
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.Explore more
Spero Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spero Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Spero Therapeutics recently announced quarterly report
Click to see if Spero Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Spero Therapeutics has new funding data
Spero Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Spero Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Spero Therapeutics
Product Launch: Get notified when Spero Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Spero Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Spero Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Spero Therapeutics
Compare insights from companies similar to Spero Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Spero Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spero Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spero Therapeutics.
Spero Therapeutics financials insights
Gather financial insights about Spero Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$33M
2016
Series B
$30M
2017
Series C
$51.7M
Grant
$6.8M
2018
Grant
$54.2M
2019
Grant
$5.9M
2021
Debt
$125M
Spero Therapeutics Tech Stack
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Product Launch, Pharmaceuticals
Person-Based
Pharmaceuticals
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Spero Therapeutics News & Media
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and Innovent Biologics, Inc. (01801.HK) today announced an exclusive license agreement for SP001 (Innovent R&D code: IBI355), a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to develop, research, manufacture, and commercialize SP001 worldwide, excluding Greater China, where Innovent retains rights. Spero currently expects to advanceUtebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis1, caused by certain susceptible pathogens2 in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved forSpero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the first quarter ended March 31, 2026, and provide a business update on Wednesday, May 13, 2026, after market close. The Company does not intend to host a conference call.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spero Therapeutics
Sign Up For FreeTo access detailed company insights
Spero Therapeutics provides therapies for treating highly resistant bacterial infections. Its headquarters is located in Cambridge, Massachusetts.... Read More
